PT  - JOURNAL ARTICLE
AU  - Klein, David M.
AU  - Poortinga, Albert
AU  - Verhoeven, Frank M.
AU  - Bonn, Daniel
AU  - Bonnet, Sylvestre
AU  - van Rijn, Cees J.M.
TI  - Degradation of lipid based drug delivery formulations during nebulization
AID  - 10.1101/2021.03.16.21253714
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.03.16.21253714
4099  - http://medrxiv.org/content/early/2021/03/24/2021.03.16.21253714.short
4100  - http://medrxiv.org/content/early/2021/03/24/2021.03.16.21253714.full
AB  - Encapsulating pharmaceuticals in protective lipid based nanoparticles, and nebulizing them towards the target area in the body offers a range of clinical advantages. However, the process of nebulization might possibly damage sensitive nanoparticle structures, such as liposomes, resulting in loss of active pharmaceutical ingredients. We compare this loss for two types of lung inhalation devices: high-frequency piezo-actuated vibrating mesh nebulizers and non-actuated continuous jet nebulizers. We find that vibrating mesh nebulizers cause model liposomes to release more than ten times as much encapsulated material as the continuous jet nebulizers because the energies involved in nebulization are much larger. This result highlights the importance of applying a mild nebulization technology when administering shear-sensitive drug formulations such as lipid nanoparticle based drugs to the lungs.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding by dutch NWO fundAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The manuscript is a medical device study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are available on request by corresponding author